FLUAD 15 MCG / 0.5 ML
HAEMAGGLUTININ-STRAIN A (H1N1) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H3N2) : 15 MCG / 0.5 ML · DIN 02362384 · SEQIRUS UK LIMITED
Health Canada status: MARKETED
What is FLUAD?
FLUAD 15 MCG / 0.5 ML contains HAEMAGGLUTININ-STRAIN A (H1N1) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H3N2) : 15 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02362384, held by SEQIRUS UK LIMITED, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 08-Sep-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FLUAD used for?
Active immunization against influenza disease caused by influenza virus subtypes A and B in the pediatric population (6 months to <2 years) and in elderly 65 years of age and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02362384 |
|---|---|
| Brand name | FLUAD |
| Generic / active ingredient | HAEMAGGLUTININ-STRAIN A (H1N1) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H3N2) : 15 MCG / 0.5 ML |
| Manufacturer | SEQIRUS UK LIMITED |
| Strength | 15 MCG / 0.5 ML |
| Dosage form | SUSPENSION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07BB02 INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 08-Sep-2017 |
| Original market date | 2011-09-10 00:00:00 |
How is it administered?
Pediatrics (6m to <2y): 0.25 mL dose. Priming requires two doses 4 weeks apart. Elderly (65+): Single 0.5 mL dose annually. Administer via intramuscular injection only.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Can be kept at room temperature (20º-25ºC) for up to 2 hours as a holding time before injection. Do not use if frozen. (Note: Standard refrigerated storage not explicitly stated in snippet).
How is it supplied?
Supplied in packages containing one or ten single dose prefilled glass syringes (Type I), without needles. Syringe plunger does not contain latex.
Contraindications
Known hypersensitivity to active substances, excipients, eggs, chicken proteins, kanamycin, neomycin sulphate, hydrocortisone, formaldehyde, CTAB, or life-threatening reaction to previous influenza vaccine.
Warnings and precautions
Do not administer intravenously. Postpone in patients with febrile illness. Use caution in patients with bleeding disorders or history of Guillain-Barré syndrome within 6 weeks of prior vaccine.
What can be used instead?
Other Canadian products sharing ATC code J07BB02 INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN. 8 of 36 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AREPANRIX H5N1 | 3.75 MCG / 0.5 ML | EMULSION | ID BIOMEDICAL CORPORATION OF QUEBEC | MARKETED | DIN 02401886 |
| FLUCELVAX | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS UK LIMITED | MARKETED | DIN 02553708 |
| FLUVIRAL | 15 MCG / 0.5 ML | SUSPENSION | ID BIOMEDICAL CORPORATION OF QUEBEC | MARKETED | DIN 02420686 |
| FLUZONE | 15 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02365936 |
| FLUZONE | 15 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02365707 |
| FLUZONE HIGH-DOSE | 60 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02445646 |
| INFLUVAC TETRA | 15 MCG / 0.5 ML | SUSPENSION | BGP PHARMA ULC | MARKETED | DIN 02484854 |
| AFLURIA TETRA | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS PTY LTD | CANCELLED POST MARKET | DIN 02473283 |
| AFLURIA TETRA | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS PTY LTD | CANCELLED POST MARKET | DIN 02473313 |
| AGRIFLU | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS UK LIMITED | CANCELLED PRE MARKET | DIN 02428881 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.